Pfizer Sues Sinotherapeutics to Block Copies of Xeljanz XR

Pfizer said Sinotherapeutics’ proposed generic version of 11-milligram Xeljanz XR infringes one of its patents on the blockbuster arthritis drug.

• Pfizer is seeking court order blocking copies until patent has expired, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• The 11-mg tablets are used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, complaint says
• Patent is titled “Tofacitinib Oral Sustained Release Dosage Forms” and expires in March 2034, complaint says
  • FDA Orange Book lists two additional patents for 11-mg strength of Xeljanz XR that aren’t at issue and expire in March 2023 and December 2025, ...